Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | FES | P07332 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.39 |
| ▸ | FER | P16591 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359421 | 1.00 | MET (0.48) | METBRD4KDRFLT3PLK4 | |
| SCHEMBL1358491 | 1.00 | MET (0.48) | METBRD4KDRFLT3PLK4 | |
| SCHEMBL1358010 | 0.89 | MET (0.40) | METBRD4KDRFLT3PLK4 | |
| SCHEMBL27910785 | 0.89 | MET (0.40) | METBRD4KDRFLT3PLK4 | |
| SCHEMBL1359293 | 0.87 | MET (0.43) | METKDRFLT3PLK4AURKA | |
| SCHEMBL1360011 | 0.87 | MET (0.41) | METBRD4KDRFLT3PLK4 | |
| SCHEMBL1357897 | 0.87 | MET (0.43) | METKDRFLT3PLK4AURKA | |
| SCHEMBL1359186 | 0.87 | MET (0.43) | METKDRFLT3PLK4AURKA | |
| SCHEMBL1359136 | 0.86 | MET (0.43) | METBRD4KDRFLT3PLK4 | |
| SCHEMBL1357571 | 0.86 | MET (0.42) | METBRD4KDRFLT3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8592448-B2 | Substituted pyrrolo[2,3-b]-pyridines and -pyrazines | OSI Pharmaceuticals, LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | OSI Pharmaceuticals, LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | OSI Pharmaceuticals, LLC | 2011-09-15 | — | — | US | disclosed |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | OSI Pharmaceuticals, LLC | 2011-09-15 | — | — | US | disclosed |
| EP-2356116-A1 | SUBSTITUTED PYRROLOÝ2,3-B¨-PYRIDINES AND-PYRAZINES | OSI Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010059771-A1 | SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES | OSI PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059771-A1 | SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES | OSI PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | MET 3/4885BRD4 461/4885KDR 112/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | MET 3/4885BRD4 461/4885KDR 112/4885 |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | MET, RET, KRAS | MET 1/4885BRD4 589/4885KDR 83/4885 |
| US-20210253571-A1 | AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR | MET, FGFR1, FGFR2 | MET 1/4885BRD4 941/4885KDR 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.